C
Chloe Orkin
Researcher at Queen Mary University of London
Publications - 229
Citations - 14129
Chloe Orkin is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Viral load & Medicine. The author has an hindex of 48, co-authored 202 publications receiving 11614 citations. Previous affiliations of Chloe Orkin include Barts Health NHS Trust & St Bartholomew's Hospital.
Papers
More filters
Posted ContentDOI
Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study
Anna Maria Geretti,Alexander J. Stockdale,Sophie H. Kelly,Muge Cevik,Simon Collins,Laura Waters,Giovanni Villa,Annemarie B Docherty,Ewen M Harrison,Lance Turtle,Peter J. M. Openshaw,J Kenneth Baillie,Caroline A. Sabin,Malcolm G Semple,Malcolm G Semple,Daniel Bradshaw,Alison E Brown,N. Connor,Valerie Delpech,Saye Khoo,Tamyo Mbisa,Chloe Orkin,Ann Sullivan,Isaric C Investigators +23 more
TL;DR: HIV-positive status may be associated with an increased risk of day-28 mortality following a COVID-19 related hospitalisation, and mortality was more common among those who were slightly older and among people with obesity and diabetes with complications.
Journal ArticleDOI
Routine HIV testing within the emergency department of a major trauma centre: a pilot study.
R. Bath,K Ahmad,Chloe Orkin +2 more
TL;DR: Despite an average uptake rate, there were 19 positive tests: eight in patients newly diagnosed, six in patients who had been lost to follow-up, and five in patients known to be positive and linked to care as mentioned in this paper.
Journal ArticleDOI
Public understanding and awareness of and response to monkeypox virus outbreak: A cross‐sectional survey of the most affected communities in the United Kingdom during the 2022 public health emergency
Sara Paparini,Ryan Whitacre,Melanie Smuk,John Thornhill,Chikondi Mwendera,Sophie Strachan,Will Nutland,Chloe Orkin +7 more
TL;DR: This paper examined the public response to public health and media messaging during the human monkeypox virus (MPXV) outbreak in the UK, focusing on at-risk communities, and found that the majority of the responses were negative.
Journal ArticleDOI
Retrospective hepatitis C seroprevalence screening in the antenatal setting—should we be screening antenatal women?
TL;DR: The addition of anti-HCV testing to the well-established antenatal screening programme provides a unique opportunity to impact on the health of pregnant women, their children, partners and future pregnancies in this new era of treatment for hepatitis C.
Journal ArticleDOI
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.
Jürgen K. Rockstroh,Chloe Orkin,Rolando M Viani,David L. Wyles,Anne F Luetkemeyer,Adriano Lazzarin,Ruth Soto-Malave,Mark Nelson,Sanjay Bhagani,Hartwig H F Klinker,Giuliano Rizzardini,Pierre-Marie Girard,Cristina Tural,Nancy S. Shulman,N. Mobashery,Yiran B Hu,Linda M Fredrick,Tami Pilot-Matias,Roger Trinh,Edward Gane +19 more
TL;DR: The OBV/PTV/r ± DSV ±RBV was well tolerated and yielded high SVR12 rates in patients with HCV genotype 1 or genotype 4/HIV-1 coinfection, regardless of treatment experience.